top of page

ANAVEX New Website - Untitled Page.png

Search

American Laboratory Magazine

Jul 21, 2015

Anavex Presents Early Evidence of Improving Cognition in Patients with Alzheimer’s Disease at AAIC 2015

Click here to read story

Recent Posts

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

bottom of page